Prakt. lékáren. 2021; 17(3): 164-169 | DOI: 10.36290/lek.2021.034

Drug problems associated with male lower urinary tract symptoms therapy

Alena Pilková1, 2, Jan Miloslav Hartinger1, 2, Petra Hrnčířová1
1 Oddělení klinické farmakologie a farmacie, Všeobecná fakultní nemocnice v Praze
2 Farmakologický ústav 1. lékařské fakulty Univerzity Karlovy, Praha

Male urinary tract symptoms (M-LUTS) belong to common complaints that are treated with drugs from several pharmacotherapeutic groups, with different mechanism of action, different mechanism of adverse affects and associated potential drug related problems. When choosing a suitable drug, it is necessary to assess patients´ general health status and concomitant medication, in order to minimize the risk of adverse effects in predisposed individuals. The text presented here summarizes current approach to the pharmacotherapy of M-LUTS and in several case reports demonstrates possible drug-related problems associated with this therapy.

Keywords: drug-related problems, alpha-1-blockers, beta-3-agonist, muscarinic receptor antagonists, vasopressin analogue, clinical pharmacy.

Published: October 12, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pilková A, Hartinger JM, Hrnčířová P. Drug problems associated with male lower urinary tract symptoms therapy. Praktické lékárenství. 2021;17(3):164-169. doi: 10.36290/lek.2021.034.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Gravas S CJ, Gacci M, Gratzke C, Herrmann TRW, C. Mamoulakis, Rieken M, Speakman MJ, Tikkinen KAO. Management of Non-neurogenic Male LUTS. EAU Guidelines. EAU Guidelines Office, Arnhem, The Netherlands., 2020.
    2. Giblo V, Louda M, Pacovský J. Přehled současné farmakoterapie LUTS. Urol. praxi, 2014; 15(3): 108-114.
    3. anon. Platná SPC. Dostupná z Databáze léků, www.sukl.cz. Státní ústav pro kontrolu léčiv 2010-.
    4. IBM Micromedex. (Ed.^(Eds) (IBM Corporation, Greenwood Village (CO))
    5. Scaglione F. How to Choose the Right Serenoa repens Extract. European Urology Supplements, 2015; 14(9): e1464-e1469. Go to original source...
    6. Chapple CR, Kaplan SA, Mitcheson D et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. Eur Urol, 2013; 63(2): 296-305. Go to original source... Go to PubMed...
    7. Havlová K. Periferní neuropatie z pohledu urologa. Urol. praxi, 2016; 17(1): 11-13. Go to original source...
    8. McVary KT CGRCea. American UrologicalAssociation Guideline: Management of Benign Prostatic Hyperplasia (BPH) Revised, 2010. American Urological Association Education and Research, Inc, 2010.
    9. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol, 1999; 36(1): 1-13. Go to original source... Go to PubMed...
    10. Djavan B, Chapple C, Milani S, Marberger M. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology, 2004; 64(6): 1081-1088. Go to original source... Go to PubMed...
    11. Sica DA. Doxazosin and congestive heart failure. Congest Heart Fail, 2002; 8(3): 178-184. Go to original source... Go to PubMed...
    12. Widimský J jr. FJ, Ceral J et al. Diagnostické a léčebné postupy u arteriální hypertenze - verze 2017. Diagnostické a léčebné postupy u arteriální hypertenze - verze 2017. Doporučení České společnosti pro hypertenzi. In: Hypertenze KV Prevence 2018; 7(Suppl): 2-22. (Ed.^(Eds)
    13. O'Mahony D, O'Sullivan D, Byrne S, O'Connor MN, Ryan C, Gallagher P. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing, 2015; 44(2): 213-218. Go to original source... Go to PubMed...
    14. Fisher E, Subramonian K, Omar MI. The role of alpha blockers prior to removal of urethral catheter for acute urinary retention in men. Cochrane Database of Systematic Reviews, (6) (2014). Go to original source...
    15. Steffel J, Verhamme P, Potpara TS et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J, 2018; 39(16): 1330-1393.. Go to original source... Go to PubMed...
    16. Han J, Jung JH, Bakker CJ, Ebell MH, Dahm P. Desmopressin for treating nocturia in men. Cochrane Database Syst Rev, 2017; 10(10): Cd012059. Go to original source... Go to PubMed...
    17. Han YK, Lee WK, Lee SH, Yang DY, Kim H. Effect of desmopressin with anticholinergics in female patients with overactive bladder. Korean journal of urology, 2011; 52(6): 396-400. Go to original source... Go to PubMed...
    18. Krakoff LR. Comments on ALLHAT and doxazosin. Current controlled trials in cardiovascular medicine, 2001; 2(6): 254-256. Go to original source... Go to PubMed...
    19. Zacà F, Benassi A, Bolzani R et al. Comparative Effects of Doxazosin and Carvedilol on Clinical Status and Left Ventricular Function in Hypertensive Patients with Mild Heart Failure. High Blood Pressure & Cardiovascular Prevention, 2005; 12(1): 37-44. Go to original source...
    20. Spoladore R, Roccaforte R, Fragasso G et al. Safety and efficacy of doxazosin as an "add-on" antihypertensive therapy in mild to moderate heart failure patients. Acta Cardiologica, 2009; 64(4): 485-491. Go to original source... Go to PubMed...
    21. Shepshelovich D, Schechter A, Calvarysky B, Diker-Cohen T, Rozen-Zvi B, Gafter-Gvili A. Medication-induced SIADH: distribution and characterization according to medication class. British journal of clinical pharmacology, 2017; 83(8): 1801-1807. Go to original source... Go to PubMed...
    22. Chapple CR. A Comparison of Varying alpha-Blockers and Other Pharmacotherapy Options for Lower Urinary Tract Symptoms. Rev Urol, 2005; 7 Suppl 4(Suppl 4): S22-30.
    23. Michel MC, Neumann HG, Mehlburger L, Schumacher H, Goepel M. Does the time of administration (morning or evening) affect the tolerability or efficacy of tamsulosin? BJU Int, 2001; 87(1): 31-34. Go to original source... Go to PubMed...
    24. Bird ST, Delaney JAC, Brophy JM, Etminan M, Skeldon SC, Hartzema AG. Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology. BMJ: British Medical Journal, 2013; 347: f6320. Go to original source... Go to PubMed...
    25. Thomas Manapurathe D, Krishna SM, Dewdney B, Moxon JV, Biros E, Golledge J. Effect of blood pressure lowering medications on leg ischemia in peripheral artery disease patients: A meta-analysis of randomised controlled trials. PLoS One, 2017; 12(6): e0178713. Go to original source... Go to PubMed...
    26. Salonia A, Eardley I, Giuliano F et al. European Association of Urology guidelines on priapism. Eur Urol, 2014; 65(2): 480-489. Go to original source... Go to PubMed...
    27. Marconi M, Pavez P, San Francisco I, Narvaez P. Priapism induced by use of tamsulosin: A case report and review of the literature. Arch Ital Urol Androl, 2019: 91(3). Go to original source... Go to PubMed...
    28. Eiland LS, Bell EA, Erramouspe J. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children. Ann Pharmacother, 2014; 48(10): 1350-1355. Go to original source... Go to PubMed...
    29. Andersohn F, Schmedt N, Weinmann S, Willich SN, Garbe E. Priapism associated with antipsychotics: role of alpha1 adrenoceptor affinity. J Clin Psychopharmacol, 2010; 30(1): 68-71. Go to original source... Go to PubMed...
    30. Spagnul SJ, Cabral PH, Verndl DO, Glina S. Adrenergic α-blockers: an infrequent and overlooked cause of priapism. Int J Impot Res, 2011; 23(3): 95-98. Go to original source... Go to PubMed...
    31. Kopeček M. Aktualizované klinické a teoretické aspekty podávání antipsychotik. Klin Farmakol Farm 2012; 26(1): 18-28.

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.